Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Learn how viral clearance from unconventional steps can add value to the total viral clearance independently or along with conventional process steps.
A comparison of in silico prediction of genotoxicity and carcinogenicity of drugs, with the results obtained from curated data in published literature.
How Syngene scientists developed a platform process for plasmid DNA production with high titers of > 1 g/L upstream with >25% recovery downstream.
Three case studies on downstream platform process development for antibody fragments, three broadly neutralizing antibodies (bNAbs) against HIV, and a new class of regenerative implant used for treating a degenerative disease.
Presenting impact of Mycoplasma contamination, available testing methods, and why Syngene prefers NAT-based Mycoplasma detection method over other methods.
Presenting the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool SynTAC-ERD, an Estrogen Receptor (ER) degrader.
In silico toxicity evaluation using Derek® Nexus for quicker and cost-effective screening for skin sensitization phototoxicity, hepatotoxicity, and in vitro hERG channel inhibition
Presenting the data for purification of Retro virus using ion exchange chromatography where the condition for purification was optimized.
Our approach to informed decision-making during early discovery stage to create novel, best-in-class drugs.
Case studies on how Syngene handled unique problems in Stability Testing arising from packaging material.